Maxwell Biosciences

Maxwell Biosciences, founded in 2016, is a preclinical drug platform company actively developing a new category of small molecule drugs called Claromers™. This novel class of drugs mimics natural antimicrobial peptides and can safely and permanently inactivate viruses. The company, composed of world-class scientists and experienced management, innovates and files new patent applications every month. Its drugs have been proven to exhibit direct activity against the structure of the herpes simplex virus (HSV-1). Our drug platform is supported by a portfolio of licensed patents and plays a critical role in the fight against emerging viral pandemics.